- $142.03m
- $151.03m
- $49.09m
- 37
- 10
- 47
- 22
Annual cashflow statement for Biodesix, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -30.7 | -31.4 | -43.2 | -65.4 | -52.1 |
| Depreciation | |||||
| Non-Cash Items | 7.85 | 11.9 | 7.17 | 20.3 | 12 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.65 | -4.8 | 4.59 | -3.44 | 14 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -21.7 | -21.4 | -28.2 | -45 | -22.9 |
| Capital Expenditures | -1.42 | -2.18 | -2.55 | -3.53 | -23.1 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.456 | -0.75 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Cash from Investing Activities | -1.87 | -2.93 | -2.55 | -3.53 | -23.1 |
| Financing Cash Flow Items | -0.119 | -8.25 | -0.5 | -17.4 | -9.04 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 23 | 81.1 | 1.26 | 58.9 | 29.1 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.626 | 56.8 | -29.5 | 10.4 | -16.8 |